PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Allergy Clin Immunol. Author manuscript; available in PMC Aug 1, 2013.
Published in final edited form as:
PMCID: PMC3410318
NIHMSID: NIHMS393054
Response to infections in persons with asthma and atopic disease: epiphenomenon or reflection of host susceptibility
Kristina M. James, MD, R. Stokes Peebles, Jr., MD, and Tina V. Hartert, MD, MPH
Vanderbilt University School of Medicine
Corresponding author: Tina V. Hartert, MD, MPH, Vanderbilt University School of Medicine, Center for Asthma & Environmental Health Sciences Research, 6107 Medical Center East, Nashville, TN 37232-8300, Phone: (615) 936-1010, Fax: (615) 936-1629, tina.hartert/at/vanderbilt.edu
Associations between respiratory infections and asthma inception and exacerbations are well established. Infant respiratory syncytial virus and rhinovirus infections are known to be associated with an increased risk of asthma development, and among children with prevalent asthma, 85% of asthma exacerbations are associated with viral infections. However, the exact nature of this relationship remains unclear. Is the increase in severity of infections an epiphenomenon, meaning respiratory infections just appear more severe in individuals with underlying respiratory disease, or instead a reflection of altered host susceptibility among persons with asthma and atopic disease? The main focus of this review is to summarize the available levels of evidence supporting or refuting the notion that persons with asthma or atopic disease have an altered susceptibility to selected pathogens, as well as discussing the biological mechanism(s) that might explain such associations. Finally, we will outline areas in need of further research, as understanding the relationships between infections and asthma has important implications for both asthma prevention and treatment, including potential new pathways that might target host immune response to select pathogens.
Keywords: Asthma, viral infections, bacterial infections, allergy, allergic rhinitis, atopic disease, immune function, immune system
Respiratory infections in asthma inception and exacerbation
A role for respiratory infections in asthma development and asthma exacerbations has been well documented (Fig 1). Infections in infancy, including respiratory syncytial virus (RSV) and rhinovirus (RV), are known to be associated with an increased risk of asthma development(1). Furthermore, this has been demonstrated to be a dose response relationship, with severe episodes of infant bronchiolitis increasing the odds of both early childhood asthma and asthma-specific morbidity(2). The same relationship exists between viral respiratory tract infections and asthma exacerbations(3;4).
Figure 1
Figure 1
Levels of clinical evidence to support an increased risk and host susceptibility to infections in the asthmatic and atopic host
Asthmatics have both increased frequency and severity of lower respiratory tract infections as compared to individuals without asthma (Fig 1). In a prospective study of RV infections in cohabitating couples consisting of one asthmatic and one non-asthmatic subject those with asthma had more frequent lower respiratory tract infections, along with symptoms which were more severe and of greater duration(5). In contrast, asthmatics(5) and those with atopic disease(6) do not appear to have increased frequency, severity, or duration of upper respiratory tract infections.
Asthma has also been identified as a risk factor for influenza-attributable morbidity and community acquired pneumonia. Influenza-attributable health care utilization, including both outpatient visits(7) and hospitalization rates(8), is higher among asthmatic children as compared to healthy children, as are influenza-related complications(9). Population-based surveillance for laboratory-confirmed influenza hospitalizations, found children with asthma to account for 32% of influenza-associated hospitalizations during the 2003-2009 influenza seasons and 44% during the 2009 H1N1 pandemic, four to five times the asthma prevalence rate(8). During the 2009 H1N1 pandemic asthmatics, as compared to non-asthmatics, were almost twice as likely to have pneumonia (50% vs. 27%) and require care in the ICU (33% vs. 19%)(9). However, in a study conducted in the UK, while asthmatics were more likely to have severe respiratory distress and require supplemental oxygen, they were half as likely to die or require an advanced level of care as compared to non-asthmatics(10). The authors found that the less severe outcomes in asthmatics were associated with prior inhaled steroid use and earlier hospital admission. Thus, asthmatics still may be at an increased risk for influenza related complications, but due to their medical history more likely to seek care earlier, resulting in improved outcomes. The risk for community acquired bacterial and viral pneumonia has been estimated to be at least two fold in patients with asthma as compared to healthy controls(11-13).
Asthmatics with allergic sensitization appear to have an even greater susceptibility to respiratory infections. Children with atopic asthma were found to experience 47% more symptomatic viral illnesses as compared to non-atopic asthmatics during peak virus season (1.19 vs. 0.81 per month)(14). Allergen sensitized asthmatics also have a higher risk of hospital admission for asthma exacerbations as compared to non-sensitized asthmatics(15).
The increased susceptibility to infections among persons with asthma extends beyond the lungs (Fig 1). Children with asthma have increased rates of both otitis media and gastroenteritis during infancy. Increased prevalence of ear infections during infancy was reported by Eldeirawi et al(16) among Mexican American asthmatic children (39%) as compared to non-asthmatic children (20%); this association was independent of antibiotic use and other infectious history. A similar relationship was noted between otitis media and both asthma and atopic dermatitis in a German birth cohort(17). A cross-sectional study of 26,400 Korean children by Ahn et al(18) identified a higher prevalence of acute gastroenteritis during infancy in children later diagnosed with asthma. Recall bias is a concern for the studies conducted by Eldeirawi(16) and Ahn(18) as they relied on retrospective reporting. In addition, patients with atopic dermatitis are highly susceptible to cutaneous bacterial, viral, and fungal infections, most notably S. aureus and herpes simplex virus(19;20). Delayed therapeutic response times and an increased likelihood of recurrence were identified for genital warts in patients with a history of hay fever, eczema, or asthma(21).
Bacterial colonization of the airways in infancy is associated with asthma development (Fig 1). Bisgaard et al(22) collected hypopharyngeal samples from 321 asymptomatic neonates at 1 month of age and found colonization of the airways with S. pneumoniae, H. influenzae, or M. catarrhalis to be associated with the development of asthma by age 5 years. We postulate this colonization is due to an altered immune response that predisposes these infants to early acquisition of these pathogens, although this colonization could also indicate a causal relationship between the pathogen and asthma inception. Increased frequency of colonization with S. pneumoniae has also been demonstrated in asthmatics. In a cross-sectional, population-based prospective study of 1,013 adolescents, asthma was an independent risk factor for nasopharyngeal colonization of S. pneumoniae, identified in 8.2% of subjects(23). An increased prevalence of bacterial colonization of the skin, primarily with S. aureus, is seen in patients with atopic dermatitis(24) and occurs on both lesional and clinically normal skin(25).
A number of latent infections have been demonstrated to be more common among subjects with asthma, including M. pneumoniae(26;27), C. pneumoniae(27;28), adenovirus(29;30), and RV(30-33). We have defined latent infections as asymptomatic bacterial or viral identification after an acute initial infection. As with colonization, we propose latent infections reflect an altered immune response, although an alternative explanation is that these pathogens may play a role in asthma pathogenesis. Mycoplasma or Chlamydia species have been identified in the airways of 45% and 11% of asthmatic subjects, respectively as compared to Mycoplasma in only 9% of normal control subjects(27). A positive relationship between Chlamydia pneumonia-specific secretory-IgA antibody levels and asthma exacerbations(28) provides further evidence for latent bacterial infection impacting asthma severity. In contrast, Sutherland et al(34) identified only 13% of suboptimally controlled asthmatics to have PCR evidence for M. pneumoniae or C. pneumoniae on lower airway endobronchial biopsy. Furthermore, the addition of clarithromycin did not improve asthma control making the clinical relevance of latent atypical bacterial infection unclear. Improved detection methods for atypical respiratory pathogens are needed to more fully characterize the relationship between these pathogens and asthma.
Latent viral infection also appears to be more common among subjects with asthma. Among 50 asymptomatic asthmatic children adenovirus was found in 78.4% of subjects, RV in 32.4%, and coronavirus in 2.7%; co-infection with two or all three viruses was also identified(30). Twenty healthy children were included as controls with only adenovirus detected in one nasopharyngeal swab. Results from other(29) but not all(27;35) studies have supported an increased prevalence of latent adenoviral infection in asthmatics likely due to varying viral detection techniques and small sample sizes. A high incidence of persistent RV infection has also been identified in asthmatics with detectable RV RNA in greater than 40% of asthmatic children 6 weeks after an acute exacerbation(31). RV RNA has also been identified in 73% of mucosal biopsies of asymptomatic patients with asthma as compared to only 22% without asthma, with the presence of human RV significantly associated with lower pulmonary lung function(33). Further studies are needed to investigate the relationship between RV persistence and asthma disease severity. Due to the finding of successive infections in children with different serotypes of human RV(36), studies which incorporate genotyping will also be helpful in determining whether what appears to be a latent RV infection in asthmatics is indeed virus persistence or conversely subsequent infections with different serotypes. This differentiation will be critical to furthering our understanding of RV infection in asthmatics and to guide future therapeutic measures including human RV-specific vaccines.
Due to the strong relationship between RSV bronchiolitis in infancy and the development of asthma(37), latent RSV infection of asthmatics has also been suggested(38). Persistent RSV infection has been documented 100 days post infection in a mouse model(39) and 5 weeks post infection in a guinea pig model(40) but similar findings have yet to be confirmed in human studies, indicating a key area in need of further research. The ability of RSV to infect(41) and persist(42) in vitro within human dendritic cells has been demonstrated and in vivo RSV persistence in human subjects has been suggested by the identification of RNA sequences homologous to the RSV genome in the naïve human bone marrow stromal cells of adult and pediatric donors, but not the complete virus(43).
Perhaps the strongest evidence for a relationship between increased infection susceptibility among persons with asthma and atopic disease is the increased rates of invasive disease (Fig 1). In a study of children with respiratory illness, rhinoviremia was detected in 25% of children presenting with an asthma exacerbation as compared to only 5% of children presenting with other respiratory conditions(44). Among persons 2 to 49 years of age enrolled in Tennessee’s Medicaid Program, the average annual incidence rate of invasive pneumococcal disease among persons with asthma was three-fold higher as compared to persons without asthma (6.1 vs. 2.0 episodes per 10,000)(45). Population-based case-control studies conducted in Minnesota(46) and Finland(47) confirmed these findings, with 17% and 5% of the invasive pneumococcal disease burden attributable to asthma within the respective population studied. An increased risk for serious pneumococcal disease for persons with atopic disease has also been demonstrated(48). Persons with atopic dermatitis are also highly susceptible to widespread disseminated viral infections including eczema mollusculatum, eczema herpeticum, and eczema vaccinatum(49). Interestingly, these conditions are not typically seen in patients with other inflammatory skin conditions, such as psoriasis(50).
A variety of potential mechanisms have been proposed to explain why those with asthma and atopic disease appear to have increased susceptibility to select viral and bacterial pathogens (Fig 2). Impaired innate immune responses have been observed in persons with asthma and atopic disease including deficient epithelial cell function, mucus overproduction, decreased interferon responses, and impaired alveolar macrophage function.
Figure 2
Figure 2
Biological mechanisms that explain an altered immune response to viral and bacterial infections in the asthmatic and atopic host
Airway Epithelium
Epithelial cells play important roles in immune responses including maintenance of barrier function, mucociliary clearance, production of peptides which have the ability to kill or neutralize microorganisms, and release of chemokines which influence antigen-specific T and B cells; deficiencies in these abilities would be expected to increase an individual’s susceptibility to infections(51). Examination of bronchial biopsies from asthmatics reveal disrupted tight junctions, an important component of epithelial barrier function, and increased permeability to macromolecules has been demonstrated in epithelial cell cultures(52). A significant association between asthma development and a proteinase inhibitor gene (SPINK5) polymorphism, postulated to impair epithelial barrier function, has also been identified within a population of German children(53). The role of atopy in host susceptibility must also be considered, as allergens have the potential to interfere with proper epithelial barrier function, and the nasal mucosal changes associated with allergic rhinitis are histologically similar to those seen in the lower airways in asthmatics(54). Peptidase allergens disrupt intercellular tight junctions in human bronchial epithelial cell lines, thereby increasing permeability of the airway epithelium(55;56) and the disruption caused by the dust mite allergen, Der p1, enhanced RSV replication within a human bronchial epithelial cell line(57). These studies shed light on how the alteration of the airway epithelium among asthmatic and atopic persons may increase susceptibility to infections.
Mucus
Mucus production is important in handling respiratory pathogens, and is both increased in quantity and viscosity in asthma. Endobronchial biopsies from asthmatic patients demonstrate airway goblet cell hyperplasia with increased numbers of mucus-secreting goblet cells in the epithelium and an increase in the size of the submucosal glands(58). RV infection in vivo increases release of the major mucin component of airway mucus secretions, MUC5AC, and in asthmatic subjects MUC5AC levels positively correlate with peak virus load(59).
Interferon Responses
Studies have shown persons with asthma and atopic disease have a deficient interferon response with significantly lower levels reported as early as birth(60), likely contributing to the future risk for respiratory viral infections. An inverse relationship between cord blood IFN-γ responses and the frequency of symptomatic viral respiratory infections has been demonstrated within the first year of life(61). Allergen exposure and RSV both reduce INF-γ production as compared to RSV infection alone in both mouse(62) and rat models(63), and may thus be synergistic in increasing host susceptibility to infection. The importance of the deficient IFN-γ production is further supported by the modulation of postviral sequelae, including significantly less bronchiolar inflammation and fibrosis, when rats with deficient IFN-γ responses receive exogenous IFN-γ supplementation during acute viral illness(64). Deficient IFN-β and IFN-λ responses to infection with RV have been demonstrated in human bronchial epithelial cells in vitro(65;66). Furthermore, the amount of IFN-λ production in bronchoalveolar lavage cells infected in vitro with RV significantly inversely correlated with clinical illness severity of the same subjects infected with RV in vivo(65), although these findings have not been replicated by others. Bochkov et al(67) and Lopez-Souza et al(68) demonstrated no difference in interferon responses in asthmatic bronchial epithelial cells in vitro in response to RV infection as compared to healthy control subjects. More recently in vitro studies in asthmatic nasal epithelial cells have demonstrated lower production of IFN-λ1 post RV infection compared to healthy control epithelium, but higher severity of illness associated with higher levels of IFN-λ1 production by asthmatics in vivo(69). How this relates to human clinical infection risk and illness severity and whether increasing interferon responses would modify morbidity still needs to be elucidated.
Alveolar Macrophages
Persons with asthma may also have impaired alveolar macrophage function. Airway macrophages from children with moderate and severe poorly controlled asthma were found to have significantly blunted phagocytosis of S. aureus and increased apoptosis(70). Children treated with inhaled corticosteroids were the control group in this study, and while that limits the interpretation, a later study(71) also supported impaired alveolar macrophage function with altered airway and intracellular airway macrophage glutathione homeostasis in children with severe asthma as compared to children with moderate asthma.
Adaptive immunity
Asthma is characterized by enhanced T helper 2 (Th2) activity(72). An increased number of CD4+T cells, predominantly Th2 cells, are seen in the airways of asthmatics, which is in contrast to the T helper 1 (Th1) cell predominance seen in normal airways(73). Delayed postnatal maturation of the immune system, including a delayed transition from Th2 to Th1 bias, is a risk factor for respiratory infections. High IL-5 production by Th2 cells at birth predicts future risk of severe respiratory infections in childhood(74); concomitant IL-10 production by T cells at birth attenuated this risk(74). In a mouse model, after infection of the lungs with Chlamydia muridarum, IL-13, a Th2 cytokine is rapidly produced and promotes susceptibility to infection, possibly related to impairment of macrophage phagocytic function(75). This may explain why allergic asthmatics, with a dominant Th2 response and enhanced IL-13 production, would be more susceptible to Chlamydial lung infection. Down-regulation of toll-like receptors (TLR) may be responsible for increased susceptibility of asthmatics to mycoplasma infection as mycoplasma clearance in an allergic mouse model has been demonstrated to be due to TLR2 downregulation(76). Impaired adaptive immune responses have been described in those with atopic dermatitis as well. Arkwright et al(77) found a significantly lower proportion of children with moderate to severe eczema to have adequate antibody responses to pneumococcal vaccination as compared to control subjects with isolated recurrent upper respiratory tract infections (17% vs. 57%). However, as the children with eczema had no history of severe or recurrent infections with S. pneumoniae, the clinical significance of their reduced response to pneumococcal vaccination is uncertain.
Alterations in immune function may be, at least in part, due to genetic influences as multiple asthma and atopic disease susceptibility genes are functional immune response genes(78;79). The GABRIEL consortium(80), a large genome-wide association study of asthma, identified a significant association for IL18R1, IL33, HLA-DQ, SMAD3, IL2RB, and ORMDL3. Many of these genes have a multitude of functions but all have been found to be involved in the Th2 inflammatory response to epithelial damage sustained during trauma or infection. A variety of genetic mutations have been identified in patients with atopic dermatitis which are associated with skin barrier dysfunction. The most commonly identified is a filaggrin mutation, present in up to 50% of patients with atopic dermatitis(81) and associated with the persistence of atopic dermatitis into adulthood(82) as well as increased asthma severity(83). The downregulation of multiple immune response genes have also been identified in patients with atopic dermatitis(50). It has also been postulated that parental asthma or allergy may influence immune function, with maternal history of atopy or asthma identified as a risk factor for more severe infant HRV-associated illness(84) and lower cytokine responses to innate stimulation by TLR2, TLR3, TLR4 and TLR9 agonists and in vitro stimulation by RSV seen in children with a parental history of allergy or asthma(85).
It has long been debated as to why asthma and atopic diseases have persisted for thousands of years and are prevalent and increasing in most populations. The enhanced Th2 activity seen in asthma and atopic disease may have a teleological basis as it confers a protective advantage against helminthic parasite infection(86-88), far more common pathogens in past centuries(89). Th2 immune signaling in the lungs of asthmatics can have deleterious effects such as increased eosinophil activity, mucus hypersecretion and muscle hyperactivity; however, these same immune mechanisms promote helminth expulsion when expressed in the gut in response to parasitic infection(90). Peisong et al(88) discovered children with upregulated Th2 immune signaling, due to an asthma associated genetic variant of STAT6, had increased resistance to infection with the helminth worm Ascaris lumbricoides. A similar relationship between atopy and helminth infection has been described in Venezuelan children(86) and in an African adult population(87). Together, these studies support a protective advantage against parasitic infections among those with asthma and atopy. It has also been proposed that the reverse is true; that parasite exposure reduces the likelihood of the development of asthma and atopic disease(91).
Other possible mechanisms for increased infection susceptibility include abnormal airway structure and function, due to prior infections and ongoing airway inflammation. Chronic responses to paramyxoviral(92) and RSV infection(93) have been demonstrated in mice consisting of airway hyperreactivity and goblet cell hyperplasia persisting for at least one year after complete viral clearance, and methacholine induced airway hyperresponsiveness up to 154 days post viral inoculation, respectively. Paramyxoviral infection has also been shown to alter epithelial cell function, characterized by decreased airway mucociliary velocity and impaired bacterial clearance(94).
Infection latency or colonization may contribute to enhanced susceptibility to infections by promoting ongoing airway inflammation. In a mouse model, trace levels of parainfluenza virus have been shown to be associated with persistent activation of the NKT cell-macrophage innate immune axis and production of IL-13 leading to chronic mucus cell metaplasia and airway hyperreactivity(95). Long-term persistence of RSV and airway hyperresponsiveness and airway eosinophilia has been demonstrated in the guinea-pig lung(38). These findings are notable, but their clinical relevance remains unclear because despite a likely role for latent parainfluenza and RSV infections in asthmatics, persistence of these viruses in humans has not been clearly established.
Lastly, there are a number of common extrinsic factors that are associated with both increased susceptibility to infection and with asthma exacerbations or asthma control, including cigarette smoke, air pollutants, and nutrition. Maternal smoking is a known risk factor for respiratory infections(96) and the development of asthma(97;98) and atopic disease(99) but has more recently also been shown to attenuate neonatal immune function with impaired TLR-mediated immune responses identified in neonates whose mothers smoked during pregnancy(100). Passive smoke exposure has also been shown in adolescents to be associated with higher rates of pneumococcal colonization of the nasopharynx(23).
Outdoor air pollutants including ozone and diesel exhaust have been implicated to alter immune function and increase infection susceptibility. Exposure to ambient ozone results in the loss of lung epithelial integrity, a key innate immune defense mechanism of the airways(101). Exposure to diesel exhaust increases the susceptibility to influenza virus infection in respiratory epithelial cells both in vitro(102) and in mice in vivo(103), possibly related to the downregulation of antimicrobial host defense molecules, including Clara cell secretory protein and surfactant proteins A and D(104).
Nutritional factors including vitamin D have also been described to impact immune function. Subclinical vitamin D levels are associated with an increased risk for respiratory tract infections in both infants(105;106) and children(107). Proposed mechanisms by which vitamin D levels modulate immune function include induction of antimicrobial peptide expression(108), downregulation of TLR expression by monocytes(109), and inhibition of T and B cell proliferation(110;111). Some of these effects strengthen the immune system whereas others actually suppress immune function, making the exact role of vitamin D in the immune system as well as the ideal circulating levels still unclear. Randomized controlled trials are ongoing to evaluate the role of vitamin D supplementation during pregnancy and asthma development(112;113).
One must also question whether any of the medications used to treat asthma or atopic disease, most notably corticosteroids, modify infection risk. Fortunately, the use of corticosteroids in asthmatics does not appear to be immunosuppressive. The association identified by Talbot et al(45) between invasive pneumococcal disease and asthma remained after adjustment for the long-term use of oral corticosteroids. Furthermore, Wos et al(33) found no relationship between inhaled corticosteroid dose and RV presence in the lower airways of patients with bronchial asthma. Nasal and inhaled corticosteroids may actually be protective in persons with allergic rhinitis or asthma by resulting in restitution of the upper and lower airway epithelium, respectively.
The suggestion of altered host susceptibility to specific viral and bacterial pathogens in persons with asthma and atopic disease has important implications for treatment and prevention. Whereas the current mainstay of therapy is inhaled corticosteroids which inhibit inflammation, more emphasis may need to be placed on therapies which bolster innate and/or adaptive immune responses in response to infection, or in deterring the long-term consequences of infection.
Other therapies which may prove beneficial include increased vaccination efforts, exogenous type I IFN administration, and glutathione supplementation. As a result of the recently demonstrated increased risk of invasive pneumococcal disease among persons with asthma, pneumococcal vaccination is now recommended for all adult asthmatics(114) and has been associated with a decrease in asthma-related hospitalizations and asthma-related length of hospital stay(115). Due to the findings of deficient IFN-β production by asthmatics, Cakebread et al(116) investigated the therapeutic potential of exogenous IFN-β administration on RV infection in asthmatics in primary bronchial epithelial cells from asthmatic donors. Treatment of cells with exogenous IFN-β followed by infection with RV resulted in a normal anti-viral response to RV, including induction of apoptosis and reduced RV replication. Intrabronchial delivery of IFN-α in an asthmatic cohort has not been effective as it induced bronchospasm with a significant decrease in FEV(117)1. Another treatment option under investigation includes the use of glutathione supplementation in patients with severe asthma as these patients have reduced levels of glutathione and subsequent impairment of airway macrophage function. Ex vivo glutathione supplementation has been demonstrated to significantly improve the phagocytic function of airway macrophages collected from severe asthmatics(71).
The relationship between infections and asthma is still not fully understood. There has been historical debate over whether respiratory infections play a causal role, or severe infections are merely a marker of those predisposed to develop asthma. The likelihood is that both are true, hosts who have a genetic propensity to develop asthma, are those who also have an altered immune response to specific pathogens, resulting in more severe infection, and that these early life events are additionally causal in asthma development. The shared pathways demonstrated by recent studies support the possibility of altered susceptibility to specific viral and bacterial pathogens within persons with asthma and atopic disease. More research is needed to characterize the innate and adaptive immune responses in asthma and atopic disease in order to both improve control of these diseases, to develop treatment strategies for those pathogens for which there are currently no therapies, and someday even prevent their development.
Abbreviations used in the manuscript and their definitions
C. pneumoniaeChlamydia pneumoniae
CD4Cluster of differentiation 4
FEV1Forced expiratory volume in 1 second
H. influenzaeHaemophilus influenzae
ICUIntensive care unit
IFNInterferon
ILInterleukin
LRTIsLower respiratory tract infections
M. catarrhalisMoraxella catarrhalis
M. pneumoniaeMycoplasma pneumoniae
NKTNatural killer T
RNARibonucleic acid
RSVRespiratory syncytial virus
RVRhinovirus
S. aureusStaphylococcus aureus
S. pneumoniaeStreptococcus pneumoniae
Th1T helper 1
Th2T helper 2
TLRToll-like receptor
URIsUpper respiratory tract infections

Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
(1) Gern JE. Viral respiratory infection and the link to asthma. Pediatr Infect Dis J. 2008;27(10 Suppl):S97–103. [PubMed]
(2) Carroll KN, Wu P, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, et al. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J Allergy Clin Immunol. 2009;123(5):1055–61. 1061. [PMC free article] [PubMed]
(3) Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ. 1995;310(6989):1225–9. [PMC free article] [PubMed]
(4) Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ. 1993;307(6910):982–6. [PMC free article] [PubMed]
(5) Corne JM, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate ST, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–4. [PubMed]
(6) Doyle WJ, Skoner DP, Fireman P, Seroky JT, Green I, Ruben F, et al. Rhinovirus infection in allergic and nonallergic subjects. J Allergy Clin Immunol. 1992;89(5):968–78. [PubMed]
(7) Miller EK, Griffin MR, Edwards KM, Weinberg GA, Szilagyi PG, Staat MA, et al. Influenza burden for children with asthma. Pediatrics. 2008;121(1):1–8. [PubMed]
(8) Dawood FS, Kamimoto L, D’Mello TA, Reingold A, Gershman K, Meek J, et al. Children With Asthma Hospitalized With Seasonal or Pandemic Influenza, 2003-2009. Pediatrics. 2011;128(1):e27–e32. [PubMed]
(9) O’Riordan S, Barton M, Yau Y, Read SE, Allen U, Tran D. Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza. CMAJ. 2010;182(1):39–44. [PMC free article] [PubMed]
(10) Semple M, Lim W, Myles P, Enstone J, Openshaw P, Read R, et al. Relationship of asthma to outcome in influenza A/H1N1 2009 infection: FLU-CIN cohort study. ERS Congress 2011 Poster Session. 2011 Ref Type: Abstract.
(11) Almirall J, Bolibar I, Serra-Prat M, Roig J, Hospital I, Carandell E, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008;31(6):1274–84. [PubMed]
(12) Teepe J, Grigoryan L, Verheij TJ. Determinants of community-acquired pneumonia in children and young adults in primary care. Eur Respir J. 2010;35(5):1113–7. [PubMed]
(13) Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract. 2009;59(567):e329–e338. [PMC free article] [PubMed]
(14) Olenec JP, Kim WK, Lee WM, Vang F, Pappas TE, Salazar LE, et al. Weekly monitoring of children with asthma for infections and illness during common cold seasons. J Allergy Clin Immunol. 2010;125(5):1001–6. [PMC free article] [PubMed]
(15) Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ. 2002;324(7340):763. [PMC free article] [PubMed]
(16) Eldeirawi K, McConnell R, Furner S, Freels S, Stayner L, Hernandez E, et al. Frequent ear infections in infancy and the risk of asthma in Mexican American children. J Asthma. 2010;47(4):473–7. [PubMed]
(17) MacIntyre EA, Chen CM, Herbarth O, Borte M, Schaaf B, Kramer U, et al. Early-life otitis media and incident atopic disease at school age in a birth cohort. Pediatr Infect Dis J. 2010;29(12):e96–e99. [PubMed]
(18) Ahn KM, Lee MS, Hong SJ, Lim DH, Ahn YM, Lee HR, et al. Fever, use of antibiotics, and acute gastroenteritis during infancy as risk factors for the development of asthma in Korean school-age children. J Asthma. 2005;42(9):745–50. [PubMed]
(19) Ring J, Abeck D, Neuber K. Atopic eczema: role of microorganisms on the skin surface. Allergy. 1992;47(4 Pt 1):265–9. [PubMed]
(20) Lubbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4(9):641–54. [PubMed]
(21) Stefanaki C, Stefanaki I, Verra P, Hadjivassiliou M, Caroni C, Bethimoutis G, et al. Atopic patients with genital warts have a more protracted clinical course and a greater probability of recurrences. Int J STD AIDS. 2010;21(10):723–7. [PubMed]
(22) Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bonnelykke K, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357(15):1487–95. [PubMed]
(23) Cardozo DM, Nascimento-Carvalho CM, Andrade AL, Silvany-Neto AM, Daltro CH, Brandao MA, et al. Prevalence and risk factors for nasopharyngeal carriage of Streptococcus pneumoniae among adolescents. J Med Microbiol. 2008;57(Pt 2):185–9. [PubMed]
(24) Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. Int J Dermatol. 1999;38(4):265–9. [PubMed]
(25) Williams JV, Vowels BR, Honig PJ, Leyden JJ. S. aureus isolation from the lesions, the hands, and the anterior nares of patients with atopic dermatitis. Pediatr Dermatol. 1998;15(3):194–8. [PubMed]
(26) Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion BP, et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med. 1998;158(3):998–1001. [PubMed]
(27) Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH. A link between chronic asthma and chronic infection. J Allergy Clin Immunol. 2001;107(4):595–601. [PubMed]
(28) Cunningham AF, Johnston SL, Julious SA, Lampe FC, Ward ME. Chronic Chlamydia pneumoniae infection and asthma exacerbations in children. Eur Respir J. 1998;11(2):345–9. [PubMed]
(29) Macek V, Sorli J, Kopriva S, Marin J. Persistent adenoviral infection and chronic airway obstruction in children. Am J Respir Crit Care Med. 1994;150(1):7–10. [PubMed]
(30) Marin J, Jeler-Kacar D, Levstek V, Macek V. Persistence of viruses in upper respiratory tract of children with asthma. J Infect. 2000;41(1):69–72. [PubMed]
(31) Kling S, Donninger H, Williams Z, Vermeulen J, Weinberg E, Latiff K, et al. Persistence of rhinovirus RNA after asthma exacerbation in children. Clin Exp Allergy. 2005;35(5):672–8. [PubMed]
(32) Malmstrom K, Pitkaranta A, Carpen O, Pelkonen A, Malmberg LP, Turpeinen M, et al. Human rhinovirus in bronchial epithelium of infants with recurrent respiratory symptoms. J Allergy Clin Immunol. 2006;118(3):591–6. [PubMed]
(33) Wos M, Sanak M, Soja J, Olechnowicz H, Busse WW, Szczeklik A. The presence of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir Crit Care Med. 2008;177(10):1082–9. [PMC free article] [PubMed]
(34) Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol. 2010;126(4):747–53. [PMC free article] [PubMed]
(35) Macek V, Dakhama A, Hogg JC, Green FH, Rubin BK, Hegele RG. PCR detection of viral nucleic acid in fatal asthma: is the lower respiratory tract a reservoir for common viruses? Can Respir J. 1999;6(1):37–43. [PubMed]
(36) Henquell C, Mirand A, Deusebis AL, Regagnon C, Archimbaud C, Chambon M, et al. Prospective genotyping of human rhinoviruses in children and adults during the winter of 2009-2010. J Clin Virol. 2012;53(4):280–4. [PubMed]
(37) Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045–52. [PubMed]
(38) Bramley AM, Vitalis TZ, Wiggs BR, Hegele RG. Effects of respiratory syncytial virus persistence on airway responsiveness and inflammation in guinea-pigs. Eur Respir J. 1999;14(5):1061–7. [PubMed]
(39) Schwarze J, O’Donnell DR, Rohwedder A, Openshaw PJ. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med. 2004;169(7):801–5. [PubMed]
(40) Riedel F, Oberdieck B, Streckert HJ, Philippou S, Krusat T, Marek W. Persistence of airway hyperresponsiveness and viral antigen following respiratory syncytial virus bronchiolitis in young guinea-pigs. Eur Respir J. 1997;10(3):639–45. [PubMed]
(41) Johnson TR, Johnson CN, Corbett KS, Edwards GC, Graham BS. Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus. PLoS One. 2011;6(1):e16458. [PMC free article] [PubMed]
(42) Hobson L, Everard ML. Persistent of respiratory syncytial virus in human dendritic cells and influence of nitric oxide. Clin Exp Immunol. 2008;151(2):359–66. [PubMed]
(43) Rezaee F, Gibson LF, Piktel D, Othumpangat S, Piedimonte G. Respiratory syncytial virus infection in human bone marrow stromal cells. Am J Respir Cell Mol Biol. 2011;45(2):277–86. [PMC free article] [PubMed]
(44) Xatzipsalti M, Kyrana S, Tsolia M, Psarras S, Bossios A, Laza-Stanca V, et al. Rhinovirus viremia in children with respiratory infections. Am J Respir Crit Care Med. 2005;172(8):1037–40. [PubMed]
(45) Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med. 2005;352(20):2082–90. [PubMed]
(46) Juhn YJ, Kita H, Yawn BP, Boyce TG, Yoo KH, McGree ME, et al. Increased risk of serious pneumococcal disease in patients with asthma. J Allergy Clin Immunol. 2008;122(4):719–23. [PMC free article] [PubMed]
(47) Klemets P, Lyytikainen O, Ruutu P, Ollgren J, Kaijalainen T, Leinonen M, et al. Risk of invasive pneumococcal infections among working age adults with asthma. Thorax. 2010;65(8):698–702. [PubMed]
(48) Jung JA, Kita H, Yawn BP, Boyce TG, Yoo KH, McGree ME, et al. Increased risk of serious pneumococcal disease in patients with atopic conditions other than asthma. J Allergy Clin Immunol. 2010;125(1):217–21. [PMC free article] [PubMed]
(49) Wollenberg A, Rawer HC, Schauber J. Innate Immunity in Atopic Dermatitis. Clin Rev Allergy Immunol. 2010 [PubMed]
(50) Grigoryev DN, Howell MD, Watkins TN, Chen YC, Cheadle C, Boguniewicz M, et al. Vaccinia virus-specific molecular signature in atopic dermatitis skin. J Allergy Clin Immunol. 2010;125(1):153–9. [PMC free article] [PubMed]
(51) Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the interface of innate and adaptive immune responses. J Allergy Clin Immunol. 2007;120(6):1279–84. [PMC free article] [PubMed]
(52) Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol. 2011;128(3):549–56. [PubMed]
(53) Kabesch M, Carr D, Weiland SK, von ME. Association between polymorphisms in serine protease inhibitor, kazal type 5 and asthma phenotypes in a large German population sample. Clin Exp Allergy. 2004;34(3):340–5. [PubMed]
(54) Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol. 2008;8(3):193–204. [PubMed]
(55) Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest. 1999;104(1):123–33. [PMC free article] [PubMed]
(56) Runswick S, Mitchell T, Davies P, Robinson C, Garrod DR. Pollen proteolytic enzymes degrade tight junctions. Respirology. 2007;12(6):834–42. [PubMed]
(57) Foster S, Bedford KJ, Gould ME, Coward WR, Hewitt CR. Respiratory syncytial virus infection and virus-induced inflammation are modified by contaminants of indoor air. Immunology. 2003;108(1):109–15. [PubMed]
(58) Ordonez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde DM, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med. 2001;163(2):517–23. [PubMed]
(59) Hewson CA, Haas JJ, Bartlett NW, Message SD, Laza-Stanca V, Kebadze T, et al. Rhinovirus induces MUC5AC in a human infection model and in vitro via NF-kappaB and EGFR pathways. Eur Respir J. 2010;36(6):1425–35. [PubMed]
(60) Tang ML, Kemp AS, Thorburn J, Hill DJ. Reduced interferon-gamma secretion in neonates and subsequent atopy. Lancet. 1994;344(8928):983–5. [PubMed]
(61) Copenhaver CC, Gern JE, Li Z, Shult PA, Rosenthal LA, Mikus LD, et al. Cytokine response patterns, exposure to viruses, and respiratory infections in the first year of life. Am J Respir Crit Care Med. 2004;170(2):175–80. [PubMed]
(62) Peebles RS, Jr., Sheller JR, Collins RD, Jarzecka AK, Mitchell DB, Parker RA, et al. Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. J Med Virol. 2001;63(2):178–88. [PubMed]
(63) Hassantoufighi A, Oglesbee M, Richter BW, Prince GA, Hemming V, Niewiesk S, et al. Respiratory syncytial virus replication is prolonged by a concomitant allergic response. Clin Exp Immunol. 2007;148(2):218–29. [PubMed]
(64) Sorkness RL, Castleman WL, Kumar A, Kaplan MR, Lemanske RF., Jr. Prevention of chronic postbronchiolitis airway sequelae with IFN-gamma treatment in rats. Am J Respir Crit Care Med. 1999;160(2):705–10. [PubMed]
(65) Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–6. [PubMed]
(66) Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–47. [PMC free article] [PubMed]
(67) Bochkov YA, Hanson KM, Keles S, Brockman-Schneider RA, Jarjour NN, Gern JE. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol. 2010;3(1):69–80. [PMC free article] [PubMed]
(68) Lopez-Souza N, Favoreto S, Wong H, Ward T, Yagi S, Schnurr D, et al. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol. 2009;123(6):1384–90. [PMC free article] [PubMed]
(69) Miller EK, Hernandez JZ, Wimmenauer V, Shepherd BE, Hijano D, Libster R, et al. A mechanistic role for type III IFN-lambda1 in asthma exacerbations mediated by human rhinoviruses. Am J Respir Crit Care Med. 2012;185(5):508–16. [PMC free article] [PubMed]
(70) Fitzpatrick AM, Holguin F, Teague WG, Brown LA. Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma. J Allergy Clin Immunol. 2008;121(6):1372–8. [PMC free article] [PubMed]
(71) Fitzpatrick AM, Teague WG, Burwell L, Brown MS, Brown LA. Glutathione oxidation is associated with airway macrophage functional impairment in children with severe asthma. Pediatr Res. 2011;69(2):154–9. [PMC free article] [PubMed]
(72) Meyer EH, DeKruyff RH, Umetsu DT. T cells and NKT cells in the pathogenesis of asthma. Annu Rev Med. 2008;59:281–92. [PubMed]
(73) Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;326(5):298–304. [PubMed]
(74) Zhang G, Rowe J, Kusel M, Bosco A, McKenna K, de KN, et al. Interleukin-10/interleukin-5 responses at birth predict risk for respiratory infections in children with atopic family history. Am J Respir Crit Care Med. 2009;179(3):205–11. [PubMed]
(75) Asquith KL, Horvat JC, Kaiko GE, Carey AJ, Beagley KW, Hansbro PM, et al. Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts. PLoS Pathog. 2011;7(5):e1001339. [PMC free article] [PubMed]
(76) Wu Q, Martin RJ, Lafasto S, Efaw BJ, Rino JG, Harbeck RJ, et al. Toll-like receptor 2 down-regulation in established mouse allergic lungs contributes to decreased mycoplasma clearance. Am J Respir Crit Care Med. 2008;177(7):720–9. [PubMed]
(77) Arkwright PD, Patel L, Moran A, Haeney MR, Ewing CI, David TJ. Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine. Clin Exp Immunol. 2000;122(1):16–9. [PubMed]
(78) Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–46. [PMC free article] [PubMed]
(79) Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev. 2011;242(1):10–30. [PMC free article] [PubMed]
(80) Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363(13):1211–21. [PubMed]
(81) O’Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010;40(7):965–72. [PubMed]
(82) Barker JN, Palmer CN, Zhao Y, Liao H, Hull PR, Lee SP, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol. 2007;127(3):564–7. [PubMed]
(83) Palmer CN, Ismail T, Lee SP, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol. 2007;120(1):64–8. [PubMed]
(84) Miller EK, Williams JV, Gebretsadik T, Carroll KN, Dupont WD, Mohamed YA, et al. Host and viral factors associated with severity of human rhinovirus-associated infant respiratory tract illness. J Allergy Clin Immunol. 2011;127(4):883–91. [PMC free article] [PubMed]
(85) Gold DR, Bloomberg GR, Cruikshank WW, Visness CM, Schwarz J, Kattan M, et al. Parental characteristics, somatic fetal growth, and season of birth influence innate and adaptive cord blood cytokine responses. J Allergy Clin Immunol. 2009;124(5):1078–87. [PMC free article] [PubMed]
(86) Lynch NR, Hagel IA, Palenque ME, Di Prisco MC, Escudero JE, Corao LA, et al. Relationship between helminthic infection and IgE response in atopic and nonatopic children in a tropical environment. J Allergy Clin Immunol. 1998;101(2 Pt 1):217–21. [PubMed]
(87) Nyan OA, Walraven GE, Banya WA, Milligan P, Van Der Sande M, Ceesay SM, et al. Atopy, intestinal helminth infection and total serum IgE in rural and urban adult Gambian communities. Clin Exp Allergy. 2001;31(11):1672–8. [PubMed]
(88) Peisong G, Yamasaki A, Mao XQ, Enomoto T, Feng Z, Gloria-Bottini F, et al. An asthma-associated genetic variant of STAT6 predicts low burden of ascaris worm infestation. Genes Immun. 2004;5(1):58–62. [PubMed]
(89) de Silva NR, Brooker S, Hotez PJ, Montresor A, Engels D, Savioli L. Soil-transmitted helminth infections: updating the global picture. Trends Parasitol. 2003;19(12):547–51. [PubMed]
(90) Isnard A, Chevillard C. Recent advances in the characterization of genetic factors involved in human susceptibility to infection by schistosomiasis. Curr Genomics. 2008;9(5):290–300. [PMC free article] [PubMed]
(91) Flohr C, Quinnell RJ, Britton J. Do helminth parasites protect against atopy and allergic disease? Clin Exp Allergy. 2009;39(1):20–32. [PubMed]
(92) Walter MJ, Morton JD, Kajiwara N, Agapov E, Holtzman MJ. Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. J Clin Invest. 2002;110(2):165–75. [PMC free article] [PubMed]
(93) Jafri HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nassi SS, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis. 2004;189(10):1856–65. [PubMed]
(94) Look DC, Walter MJ, Williamson MR, Pang L, You Y, Sreshta JN, et al. Effects of paramyxoviral infection on airway epithelial cell Foxj1 expression, ciliogenesis, and mucociliary function. Am J Pathol. 2001;159(6):2055–69. [PubMed]
(95) Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med. 2008;14(6):633–40. [PMC free article] [PubMed]
(96) DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children’s health. Pediatrics. 2004;113(4 Suppl):1007–15. [PubMed]
(97) Han YY, Lee YL, Guo YL. Indoor environmental risk factors and seasonal variation of childhood asthma. Pediatr Allergy Immunol. 2009;20(8):748–56. [PubMed]
(98) Karmaus W, Dobai AL, Ogbuanu I, Arshard SH, Matthews S, Ewart S. Long-term effects of breastfeeding, maternal smoking during pregnancy, and recurrent lower respiratory tract infections on asthma in children. J Asthma. 2008;45(8):688–95. [PMC free article] [PubMed]
(99) Schafer T, Dirschedl P, Kunz B, Ring J, Uberla K. Maternal smoking during pregnancy and lactation increases the risk for atopic eczema in the offspring. J Am Acad Dermatol. 1997;36(4):550–6. [PubMed]
(100) Noakes PS, Hale J, Thomas R, Lane C, Devadason SG, Prescott SL. Maternal smoking is associated with impaired neonatal toll-like-receptor-mediated immune responses. Eur Respir J. 2006;28(4):721–9. [PubMed]
(101) Broeckaert F, Arsalane K, Hermans C, Bergamaschi E, Brustolin A, Mutti A, et al. Serum clara cell protein: a sensitive biomarker of increased lung epithelium permeability caused by ambient ozone. Environ Health Perspect. 2000;108(6):533–7. [PMC free article] [PubMed]
(102) Jaspers I, Ciencewicki JM, Zhang W, Brighton LE, Carson JL, Beck MA, et al. Diesel exhaust enhances influenza virus infections in respiratory epithelial cells. Toxicol Sci. 2005;85(2):990–1002. [PubMed]
(103) Ciencewicki J, Gowdy K, Krantz QT, Linak WP, Brighton L, Gilmour MI, et al. Diesel exhaust enhanced susceptibility to influenza infection is associated with decreased surfactant protein expression. Inhal Toxicol. 2007;19(14):1121–33. [PubMed]
(104) Gowdy K, Krantz QT, Daniels M, Linak WP, Jaspers I, Gilmour MI. Modulation of pulmonary inflammatory responses and antimicrobial defenses in mice exposed to diesel exhaust. Toxicol Appl Pharmacol. 2008;229(3):310–9. [PubMed]
(105) Karatekin G, Kaya A, Salihoglu O, Balci H, Nuhoglu A. Association of subclinical vitamin D deficiency in newborns with acute lower respiratory infection and their mothers. Eur J Clin Nutr. 2009;63(4):473–7. [PubMed]
(106) Morales E, Romieu I, Guerra S, Ballester F, Rebagliato M, Vioque J, et al. Maternal Vitamin D Status in Pregnancy and Risk of Lower Respiratory Tract Infections, Wheezing, and Asthma in Offspring. Epidemiology. 2012;23(1):64–71. [PubMed]
(107) Wayse V, Yousafzai A, Mogale K, Filteau S. Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. Eur J Clin Nutr. 2004;58(4):563–7. [PubMed]
(108) Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–12. [PubMed]
(109) Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006;36(2):361–70. [PubMed]
(110) Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179(3):1634–47. [PubMed]
(111) Karmali R, Hewison M, Rayment N, Farrow SM, Brennan A, Katz DR, et al. 1,25(OH)2D3 regulates c-myc mRNA levels in tonsillar T lymphocytes. Immunology. 1991;74(4):589–93. [PubMed]
(112) Brigham and Women’s hospital; National Heart, Lung, and Blood Institute Randomized trial: maternal vitamin D supplementation to prevent childhood asthma (VDAART) National Library of Medicine (US); Bethesda (MD): 2000. ClinicalTrials.gov[Internet] [cited 2012 Feb 20]. Available from: http://clinicaltrials.gov/show/NCT00920621 NLM Identifier: NCT 00920621.
(113) Copenhagen studies on asthma in childhood Vitamin D supplementation during pregnancy for prevention of asthma in childhood (ABCvitamin D) National Library of Medicine (US); Bethesda (MD): 2000. ClinicalTrials.gov[Internet] [cited 2012 Feb 20]. Available from: http://clinicaltrials.gov/show/NCT00856947 NLM Identifier: NCT 00856947.
(114) Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23) MMWR Morb Mortal Wkly Rep. 2010;59(34):1102–6. [PubMed]
(115) Ansaldi F, Turello V, Lai P, Bastone G, De LS, Rosselli R, et al. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. J Int Med Res. 2005;33(5):490–500. [PubMed]
(116) Cakebread JA, Xu Y, Grainge C, Kehagia V, Howarth PH, Holgate ST, et al. Exogenous IFN-beta has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol. 2011;127(5):1148–54. [PubMed]
(117) Krasnowska M, Malolepszy J, Liebhart E, Inglot AD. Inhaled natural human interferon alpha induces bronchospastic reactions in asthmatics. Arch Immunol Ther Exp (Warsz) 1992;40(1):75–8. [PubMed]